Milan Unit, Institute of Genetic and Biomedical Research (IRGB), National Research Council, 20138, Milan, Italy.
Osteoporos Int. 2012 Nov;23(11):2713-8. doi: 10.1007/s00198-011-1878-5. Epub 2012 Jan 10.
Here we report 41 novel mutations in the TCIRG1 gene that is responsible for the disease in more than 50% of ARO patients. The characterisation of mutations in this gene might be useful in the process of drug design for osteoporosis treatment.
Autosomal recessive osteopetrosis (ARO) is a genetically heterogeneous disorder due to reduced bone resorption by osteoclasts. In this process, a crucial role is played by the proton pump V-ATPase. Biallelic mutations in the TCIRG1 gene, encoding for the a3 subunit of this pump, are responsible for more than one half of ARO patients.
Patients with a clinical diagnosis of ARO have been collected for 7 years and mutation analysis of the TCIRG1 gene was performed using direct DNA sequencing of PCR-amplified exons according to both a standard protocol and a modified one.
We report here 41 novel mutations identified in 67 unpublished patients, all with biallelic mutations. In particular, we describe two novel large genomic deletions and two splice site mutations in the 5' UTR of the TCIRG1 gene, in patients previously classified as mono-allelic.
Our data highlights the importance of two large genomic deletions and mutations in the 5' UTR with respect to patient management and, more critically, to prenatal diagnosis. With the present work, we strongly contribute to the molecular dissection of TCIRG1-deficient ARO and identify several protein residues which are fundamental for proton pump function and could thus be the target of future drugs designed to inhibit osteoclast resorptive activity.
在这里,我们报告了 TCIRG1 基因的 41 个新突变,该基因负责超过 50%的 ARO 患者的疾病。该基因突变的特征可能有助于骨质疏松症治疗药物设计的过程。
常染色体隐性骨硬化症(ARO)是一种遗传异质性疾病,由于破骨细胞的骨吸收减少。在这个过程中,质子泵 V-ATPase 起着至关重要的作用。TCIRG1 基因的双等位基因突变,该基因编码该泵的 a3 亚基,负责超过一半的 ARO 患者。
收集了 7 年来具有 ARO 临床诊断的患者,并使用根据标准方案和改良方案对 PCR 扩增的外显子进行直接 DNA 测序,对 TCIRG1 基因进行突变分析。
我们在此报告了 67 名未发表患者中发现的 41 种新突变,所有患者均为双等位基因突变。特别是,我们在 TCIRG1 基因的 5'UTR 中描述了两个新的大片段缺失和两个剪接位点突变,这些患者以前被归类为单等位基因突变。
我们的数据强调了两个大片段缺失和 5'UTR 突变在患者管理方面的重要性,更重要的是,在产前诊断方面。通过目前的工作,我们为 TCIRG1 缺陷性 ARO 的分子剖析做出了重要贡献,并确定了几个对质子泵功能至关重要的蛋白质残基,因此可能成为未来旨在抑制破骨细胞吸收活性的药物的靶点。